Zai Lab's Revenue Trajectory Keeps Bending in the Wrong Direction—Or Does It

Zai Lab Ltd (NASDAQ: ZLAB) reports second-quarter 2026 earnings before market open on August 6, 2026. With the biotechnology company trading near its 52-week lows and analyst sentiment improving despite persistent losses, investors will scrutinize whether ZLAB can demonstrate progress toward profitability while maintaining revenue growth momentum in its commercial oncology portfolio.

Part 1: Earnings Preview

Zai Lab is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for oncology, autoimmune, and infectious diseases primarily in China and other Asian markets. The company has built a portfolio of approved products including ZEJULA (niraparib) for ovarian cancer and QINLOCK (ripretinib) for gastrointestinal stromal tumors.

ZLAB is scheduled to report Q2 2026 results before market open on August 6, with analyst consensus calling for an EPS loss of $0.67 and revenue of $103.87 million. The company most recently reported Q1 2026 EPS of $-0.46, beating estimates of $-0.58 by 20.69%. Year-over-year, the expected Q2 loss of $0.67 compares to a loss of $0.37 in Q2 2025, representing a significant deterioration as the company continues investing heavily in its pipeline and commercial infrastructure.

Three key themes define this earnings story:

Commercial Execution and Revenue Trajectory: With Q2 revenue expected at $103.87 million (up 46% year-over-year from prior quarter comparisons), investors will focus on whether ZLAB's oncology franchises are gaining traction. The company missed revenue estimates in Q1 despite beating on EPS, raising questions about demand trends for its key products.

Path to Profitability: The widening expected loss versus last year reflects ongoing R&D investments and commercial expansion costs. Analysts project full-year 2026 losses of $2.23 per share, a 39% deterioration from 2025. Management's commentary on operating leverage and timeline to breakeven will be critical.

Pipeline Progress and Regulatory Milestones: Any updates on clinical trial readouts, regulatory submissions, or partnership developments could significantly impact the stock. With a strong analyst consensus (8 Strong Buys) despite the losses, the Street appears to be betting on ZLAB's long-term pipeline value rather than near-term profitability.

Analysts maintain a bullish stance heading into the print, with the average price target of $35.64 implying 94% upside from current levels. The consensus has improved recently, with one analyst upgrading from Strong Sell to Hold over the past month, pushing the average recommendation to 4.45 (solidly in Buy territory).

Part 2: Historical Earnings Performance

Zai Lab has demonstrated a mixed but generally positive track record of earnings execution over the past four quarters. In Q1 2026, the company reported a loss of $0.46 versus estimates of $0.58, delivering a strong 20.69% beat. However, Q4 2025 saw a modest 4.55% miss with a loss of $0.46 against expectations of $0.44, while Q3 2025 missed by 17.86% with a $0.33 loss versus the $0.28 estimate.

The pattern reveals inconsistency in ZLAB's ability to meet Street expectations, though the magnitude of beats and misses has been relatively contained. The Q2 2025 result came in exactly in line with estimates at a $0.37 loss. What's notable is the trajectory of losses: while the company beat significantly in the most recent quarter, the absolute loss levels have remained stubbornly elevated in the $0.33 to $0.46 range over the past year.

This earnings history suggests investors should expect volatility in results relative to estimates, with the company's ability to control costs and drive operating leverage remaining uncertain. The 20.69% beat last quarter may have reset expectations, making the bar higher for this upcoming release.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Zai Lab typically reports earnings before market open, meaning Day 0 captures the market's immediate reaction during the first trading session after results are released, while Day +1 reflects follow-through momentum.

ZLAB exhibits significant post-earnings volatility, with an average absolute Day 0 move of 5.04% and Day +1 move of 3.61%. The stock's reaction has been predominantly negative in recent quarters, with five of the last eight earnings releases resulting in Day 0 declines. The most dramatic move came in August 2025 with an 11.98% Day 0 drop, followed by substantial declines of 6.85% (November 2024) and 6.65% (November 2025).

The Day 0 trading range averages 8.10%, indicating substantial intraday volatility as investors digest results and management commentary. Interestingly, Day +1 moves have sometimes reversed the initial reaction, as seen in August 2025 when a sharp Day 0 decline was followed by a 2.58% Day +1 recovery. Recent quarters show somewhat more muted reactions, with the February and May 2026 reports producing Day 0 moves of 1.55% and -5.93% respectively, suggesting the market may be recalibrating expectations for this growth-stage biotech.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 6.71% for the August 21 expiration, which sits between the historical Day 0 average of 5.04% and the Day 0 range average of 8.10%. This suggests options traders are anticipating a moderately volatile reaction, though not as extreme as some of ZLAB's larger historical swings like the 11.98% drop in August 2025.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Zai Lab with an average recommendation of 4.45 (Buy) and a mean price target of $35.64, implying substantial 94% upside from the current price of $18.37. The consensus includes 8 Strong Buy ratings, 3 Hold ratings, and no Sell recommendations among the 11 analysts covering the stock.

Sentiment has improved over the past month, with one analyst upgrading from Strong Sell to Hold, reflecting growing confidence despite the company's ongoing losses. The average recommendation strengthened from 4.27 a month ago to the current 4.45, indicating analysts are becoming more constructive on the stock's prospects.

Price targets range from a low of $21.60 to a high of $52.00, with the wide spread reflecting differing views on the timeline and magnitude of ZLAB's commercial success. Even the most conservative target implies 18% upside, while the bull case sees potential for nearly 3x returns. This optimistic consensus suggests analysts believe the market is significantly undervaluing ZLAB's oncology portfolio and pipeline potential, viewing current losses as an investment phase rather than a structural concern.

Part 4: Technical Picture

Zai Lab enters earnings with deteriorating technical momentum, as the Barchart Technical Opinion has shifted sharply bearish. The signal currently stands at 88% Sell, up from 64% Sell last week and just 40% Sell a month ago, indicating accelerating negative momentum heading into the release.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal suggests near-term pressure but not extreme bearishness
• Medium-term (100% Sell): Strong sell signal indicates clear weakness in the intermediate trend
• Long-term (100% Sell): Strong sell signal reflects persistent weakness in the longer-term trend structure

Trend Characteristics: The trend is characterized as Weak strength with Average direction, suggesting a lack of conviction in either direction but with the balance tilted toward continued weakness heading into the earnings catalyst.

The stock is trading at $18.37, positioned below most key moving averages including the 10-day ($18.60), 20-day ($19.41), 50-day ($18.59), 100-day ($19.47), and 200-day ($19.77). The stock sits just above its 5-day moving average of $18.30, providing minimal near-term support.

ZLAB is trading near its 52-week low of $15.96 and well below its 52-week high of $39.64, reflecting sustained selling pressure throughout 2026. The concentration of moving averages in the $18.60-$19.77 range creates a significant resistance zone overhead. With the stock below all major moving averages except the 5-day and technical indicators flashing strong sell signals across multiple timeframes, the setup heading into earnings is decidedly cautious. Any disappointment could test the $15.96 support level, while a significant beat would need to overcome substantial technical resistance to spark a sustained rally.